Search
for
Sort by
Research 91–120 of 1000+
- Alopecia areata – Current understanding and management
- Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial
- The Potential Relevance of the Microbiome to Hair Physiology and Regeneration: The Emerging Role of Metagenomics
- Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
- Current standards in the diagnostics and therapy of hair diseases - hair consultation
- Optical coherent tomography: promising in vivo measurement of hair shaft cross section
- Selected variants of the melanocortin 4 receptor gene (MC4R) do not confer susceptibility to female pattern hair loss
- Infundibular protein and RNA microarray analyses from affected and clinically non-affected scalp in male androgenetic alopecia patients
- Evaluation of trichodynia (hair pain) during chemotherapy or tamoxifen treatment in breast cancer patients
- Androgenetische Alopezie
- Skin health and integrity
- Differential expression of mTOR signaling pathway proteins in lichen planopilaris and frontal fibrosing alopecia
- Efficacy and safety of a new 5% minoxidil formulation in male androgenetic alopecia: A randomized, placebo‐controlled, double‐blind, noninferiority study
- The oestrogen receptor 2 (<i>ESR2</i>) gene in female-pattern hair loss: replication of association with rs10137185 in German patients
- Quality of life, psychosocial difficulties and bullying in paediatric patients with alopecia areata: a European cross-sectional study
- Efficacy and safety of Cinainu in paediatric alopecia areata: an international, double-blind, randomized, placebo-controlled, phase II/III trial
- Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment
- Aktuelle Standards zur Diagnostik und Therapie von Haarerkrankungen — Haarsprechstunde
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- Statement from the frontal fibrosing alopecia international expert alliance: SOFFIA 2024
- Comorbid Bronchial Asthma, Atopic Dermatitis and Hashimoto's Thyroiditis Are Risk Factors for Early‐Onset, Severe and Prolonged Alopecia Areata
- Physician- and Patient-Reported Severity and Quality of Life Impact of Alopecia Areata: Results from a Real-World Survey in Five European Countries
- Alopecia areata – Aktuelles Verständnis und Management
- 272 Structural changes in human skin after topical application of glucocorticoids assessed by in vivo imaging technologies
- A Phase III, Multicenter, Parallel-Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam Versus Vehicle in Women With Female Pattern Hair Loss.
- Efficacy and Safety of Once-Daily Minoxidil Foam 5% Versus Twice-Daily Minoxidil Solution 2% in Female Pattern Hair Loss: A Phase III, Randomized, Investigator-Blinded Study.
- Expression of melanocortin receptors on cutaneous fibroblastic cells – collagen and beyond
- Melanocortin receptors in fibroblastic cell types of the skin –<i>in vitro</i> and <i>in vivo</i> expression and functional relevance
- S3‐Leitlinie Diagnostik und Therapie der Alopecia areata – Teil 2: Therapie, psychosoziale und kosmetische Unterstützung
- S3‐Leitlinie Diagnostik und Therapie der Alopecia areata – Teil 1: Diagnostik und Epidemiologie